In Vitro Antiviral Activity of Cabotegravir against HIV-2
作者： Robert A. Smith , Vincent H. Wu , Christopher G. Zavala , Dana N. Raugi , Selly Ba
DOI: 10.1128/AAC.01299-18
关键词: Cabotegravir 、 Integrase inhibitor 、 Virology 、 Medicine 、 Human immunodeficiency virus (HIV) 、 Clinical trial 、 In vitro 、 West africa 、 Antiretroviral therapy
摘要: We examined the antiviral activity of integrase inhibitor (INI) cabotegravir against HIV-2 isolates from INI-naive individuals. was sensitive to in single-cycle and spreading-infection assays, with 50% effective concentrations (EC50s) low subnanomolar range; comparable results were obtained for HIV-1 both assay formats. Our findings suggest that should be evaluated clinical trials as a potential option antiretroviral therapy preexposure prophylaxis HIV-2-prevalent settings.
sci-hub.se 参考文章(70)
Daniela Francisci, Laura Martinelli, Liliana E. Weimer, Maurizio Zazzi, Marco Floridia, Giulia Masini, Franco Baldelli, HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance Clinical Drug Investigation. ,vol. 31, pp. 345- 349 ,(2012) , 10.1007/BF03256933
Christophe Pannecouque, Walid Heneine, Thomas M. Folks, Myriam Witvrouw, Erik De Clercq, William M. Switzer, Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral Therapy. ,vol. 9, pp. 57- 65 ,(2004)
David A Margolis, Cynthia C Brinson, Graham H R Smith, Jerome de Vente, Debbie P Hagins, Joseph J Eron, Sandy K Griffith, Marty H St Clair, Marita C Stevens, Peter E Williams, Susan L Ford, Britt S Stancil, Melinda M Bomar, Krischan J Hudson, Kimberly Y Smith, William R Spreen, Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial Lancet Infectious Diseases. ,vol. 15, pp. 1145- 1155 ,(2015) , 10.1016/S1473-3099(15)00152-8
Robert A. Smith, Dana N. Raugi, Charlotte Pan, Matthew Coyne, Alexandra Hernandez, Brad Church, Kara Parker, James I. Mullins, Papa Salif Sow, , Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens PLOS ONE. ,vol. 7, ,(2012) , 10.1371/JOURNAL.PONE.0045372
Sophie Matheron, Sophie Pueyo, Florence Damond, François Simon, Annie Leprêtre, Pauline Campa, Roger Salamon, Genevieve Chêne, Françoise Brun-Vezinet, French HIV-2 Cohort Study Group, Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS. ,vol. 17, pp. 2593- 2601 ,(2003) , 10.1097/00002030-200312050-00006
Kevin Peterson, Jean Ruelle, Marc Vekemans, Frederick P Siegal, Jane R Deayton, Robert Colebunders, The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series Antiviral Therapy. ,vol. 17, pp. 1097- 1100 ,(2012) , 10.3851/IMP2303
Kristen Andreatta, Michael D Miller, Kirsten L White, None, HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. Journal of Acquired Immune Deficiency Syndromes. ,vol. 62, pp. 367- 374 ,(2013) , 10.1097/QAI.0B013E31827B55F1
C. D. Andrews, W. R. Spreen, H. Mohri, L. Moss, S. Ford, A. Gettie, K. Russell-Lodrigue, R. P. Bohm, C. Cheng-Mayer, Z. Hong, M. Markowitz, D. D. Ho, Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus Science. ,vol. 343, pp. 1151- 1154 ,(2014) , 10.1126/SCIENCE.1248707
Florence Damond, Sylvie Lariven, Benedicte Roquebert, Sylvia Males, Gilles Peytavin, Genevieve Morau, Daniel Toledano, Diane Descamps, Francoise Brun-Vezinet, Sophie Matheron, Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS. ,vol. 22, pp. 665- 666 ,(2008) , 10.1097/QAD.0B013E3282F51203
Luis Menéndez-Arias, Mar Álvarez, Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection Antiviral Research. ,vol. 102, pp. 70- 86 ,(2014) , 10.1016/J.ANTIVIRAL.2013.12.001